Live Feeds
● TRACKER Updated 20d ago · 48 sources tracked

Will FDA advisers recommend a multi-cancer blood test for approval? They'll vote

FDA advisers voted 7-2 that the benefits of Grail's Galleri blood test outweigh its risks, though the final decision rests with the FDA. The panel voted 10-0 on safety and 6-4 on effectiveness for the test, which scans healthy individuals for signals associated with over 50 types of cancer. While the recommendation marks a major regulatory step, critics argue the test failed its own large trial and could lead to increased false positives and wasted spending. Healthcare providers are now developing strategies to use the technology responsibly if approved.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~3 min
Speed:
RSS Source map (48)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ FDA advisers voted 7-2 that Grail's Galleri blood test benefits outweigh its risks.
  • ✓ The advisory panel voted 10-0 on safety and 6-4 on effectiveness.
  • ✓ The Galleri test scans for signals associated with more than 50 types of cancer in healthy people.
  • ✓ The FDA advisory panel recommendation is nonbinding.
🛡️ Source Corroboration: 48 independent reporting domains (90% confidence) ⏱ Read time: ~2 min

What changed

Recent reports highlight a divide between the advisory panel's recommendation and critics who claim the Galleri test failed its own major trial.

Live updates

  1. FDA Advisers Recommend Approval for Grail Galleri Multi-Cancer Blood Test

    FDA advisers voted 7-2 that the benefits of Grail's Galleri blood test outweigh its risks, though the final decision rests with the FDA. The panel voted 10-0 on safety and 6-4 on effectiveness for the test, which scans healthy individuals for signals associated with over 50 types of cancer. While the recommendation marks a major regulatory step, critics argue the test failed its own large trial and could lead to increased false positives and wasted spending. Healthcare providers are now developing strategies to use the technology responsibly if approved.

    Why it matters

    Multi-cancer early detection tests aim to identify various malignancies from a single blood draw before symptoms appear. Approval would establish a new regulatory precedent for screening healthy populations. The process remains contentious due to disagreements over the clinical utility of the trial data.

    What is confirmed

    • FDA advisers voted 7-2 that Grail's Galleri blood test benefits outweigh its risks.
    • The advisory panel voted 10-0 on safety and 6-4 on effectiveness.
    • The Galleri test scans for signals associated with more than 50 types of cancer in healthy people.
    • The FDA advisory panel recommendation is nonbinding.

    Still unconfirmed

    • The test would increase false positives and waste billions of dollars.

    What to watch next

    • The final FDA decision on the Galleri test approval
    • Clinical data release from the NHS-Galleri trial review
    Sources used for this update (7)
    1. www.patientcareonline.com — FDA Grants Breakthrough Device Designation to Natera's Multi ...
    2. dnyuz.com — A blood test for 50-plus cancers? One survivor is glad he ...
    3. www.feedzop.com — New Blood Test for Early Cancer Detection Nears FDA Approval
    4. geneticliteracyproject.org — Viewpoint: RFK Jr.’s stacked FDA advisory council endorses ...
    5. www.medtechdive.com — 5 doctors weigh in on the promise, limitations of Grail’s ...
    6. www.sensible-med.com — A Formal Review of the Grail Cancer Detection Trial
    7. cancerletter.com — VCU’s Baskin and UNC’s Ferris weigh oncology’s looming ...
    confidence 90%

  2. FDA advisers back Grail's multi-cancer blood test

    US FDA advisers voted 7-2 that Grail's Galleri blood test benefits outweigh its risks, with a 10-0 vote on safety and a 6-4 vote on effectiveness. The test scans for signals associated with multiple cancer types in healthy people. While the recommendation is a major regulatory milestone, it is nonbinding, leaving the final decision to the FDA. The test's approval would be a significant step forward in cancer detection.

    Why it matters

    The FDA's advisory committee guidance will influence but not guarantee the approval of Grail's Galleri blood test. If approved, the test could become a new tool for early cancer detection in adults aged 50 and older. The test's impact on mortality rates remains uncertain. Other companies, such as Natera, are also developing multi-cancer blood tests.

    What is confirmed

    • An FDA advisory committee voted 7-2 that Grail's Galleri blood test benefits outweigh its risks.
    • The FDA advisory committee voted 10-0 on the safety of Grail's Galleri blood test.
    • The FDA advisory committee voted 6-4 on the effectiveness of Grail's Galleri blood test.
    • Natera's multi-cancer blood test received FDA Breakthrough Device designation on October 9, 2026.

    Still unconfirmed

    • No MCED blood test has proven a mortality benefit

    What to watch next

    • FDA decision on Grail's Galleri blood test
    • Insurance coverage for Grail's Galleri blood test
    • Natera's multi-cancer blood test approval
    Sources used for this update (7)
    1. cancerletter.com — As FDA sidesteps the question of Galleri’s clinical benefit ...
    2. insights.citeline.com — Galleri Panel Aftermath: What Investors And Rivals See Next ...
    3. www.medicaldaily.com — Natera's Multi-Cancer Blood Test Gets FDA Breakthrough Status ...
    4. www.pharmawire.org — Grail's cancer blood test nears landmark FDA approval, but ...
    5. www.targetedonc.com — FDA Grants Breakthrough Status to Multi-Cancer Early ...
    6. mugglehead.com — Natera gains FDA breakthrough designation for MCED test
    7. nexi.fund — Twelve Cancers, One Blood Draw: Natera Wins FDA Breakthrough ...
    confidence 85%

  3. FDA Advisory Panel Backs Grail Multi-Cancer Blood Test

    Federal health advisers endorsed Grail's Galleri blood test, moving the screening tool closer to potential federal approval for adults aged 50 and older. An advisory committee voted 7-2 with one abstention that the test's benefits outweigh its risks, alongside a 10-0 vote on safety and a 6-4 vote on effectiveness. The blood test scans for signals associated with multiple cancer types in apparently healthy people. While the recommendation marks a major regulatory milestone, committee advice is nonbinding, leaving the final decision on the premarket approval application to the Food and Drug Administration.

    Why it matters

    The Food and Drug Administration is a federal agency responsible for protecting public health by ensuring the safety and efficacy of medical devices and biological products. Grail's test is designed to spot signs of various cancers before symptoms appear, but major clinical trials have left questions about whether finding more cancers through the screening will ultimately improve patient survival. Additional considerations involve the test's cost, which stands at $949, and future insurance coverage.

    What is confirmed

    • An FDA advisory committee voted 7-2 with one abstention that Galleri's benefits outweigh its risks.
    • The panel voted 10-0 on safety and 6-4 on whether there was reasonable assurance the test is effective.
    • The blood-based test is designed by Grail to identify signals associated with multiple cancers in adults 50 and older.
    • Advisory committee recommendations are nonbinding, and the Food and Drug Administration makes the final decision on a premarket approval application.

    Still unconfirmed

    • The final agency decision from the Food and Drug Administration is expected within months.

    What to watch next

    • Final regulatory decision by the Food and Drug Administration on the premarket approval application
    • Developments regarding insurance coverage and test pricing
    Sources used for this update (14)
    1. www.fda.gov — U.S. Food and Drug Administration
    2. www.fda.gov — Drugs | FDA
    3. en.wikipedia.org — Food and Drug Administration - Wikipedia
    4. www.usa.gov — Food and Drug Administration (FDA) | USAGov
    5. www.fda.gov — About FDA | FDA - U.S. Food and Drug Administration
    6. www.fda.gov — Food | FDA
    7. www.marketscreener.com — Grail's cancer blood test nears landmark FDA approval, but insurance coverage looms | MarketScreener
    8. www.cherokeephoenix.org — FDA panel endorses first-of-a-kind cancer blood test from ...
    9. patientworthy.com — Galleri Moves Closer to FDA Decision as Evidence on Multi ...
    10. www.medicaldaily.com — Cancer Blood Test Galleri Nears FDA Decision as Screening ...
    11. lifescivoice.com — Grail's Cancer Blood Test Nears Landmark FDA Approval
    12. www.clinicaltrialvanguard.com — FDA Advisory Panel Votes 7-2 to Support Galleri Multi-Cancer ...
    confidence 100%

  4. FDA Panel Backs Grail Galleri Multi-Cancer Blood Test

    An FDA advisory panel voted that the benefits of Grail's Galleri blood test outweigh its risks, moving the company closer to federal approval. The panel also voted 6-4 that the screening tool is effective. The test scans healthy individuals for more than 50 cancer types before symptoms appear. While the panel provided a milestone win, its decision is not a final agency approval. Previous concerns centered on whether the test detects disease early enough to reduce mortality rates.

    Why it matters

    The Galleri test is a multi-cancer early detection tool designed for use in asymptomatic people. Early detection of multiple cancers via a single blood draw could change screening protocols if approved. The FDA uses these advisory panels to gauge expert consensus before making a final regulatory decision.

    What is confirmed

    • An FDA advisory panel voted 7-2 that the benefits of Grail's Galleri test outweigh its risks.
    • The panel voted 6-4 that the screening tool is effective.
    • The Galleri test is designed to screen for more than 50 types of cancer in healthy individuals.
    • The advisory panel vote does not constitute final FDA approval.

    What to watch next

    • Final FDA approval decision
    • Insurance coverage determinations for the test
    Sources used for this update (3)
    1. www.ktvu.com — Bay Area biotech's groundbreaking blood test to detect 50+ cancers gets critical FDA panel approval | KTV....
    2. finance.yahoo.com — Grail's cancer blood test nears landmark FDA approval, but ...
    3. northlandnewsradio.com — Grail’s cancer blood test nears landmark FDA approval, but ...
    confidence 100%

  5. FDA Panel Backs Grail Multi-Cancer Test in Advisory Vote

    An expert advisory panel voted 7-2 that the benefits of Grail's Galleri multi-cancer blood test outweigh its risks, and 6-4 that the screening tool is effective. The vote by the FDA Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is not a final approval by the agency. The blood test is designed to scan for signs of more than fifty cancer types in healthy individuals before symptoms manifest. Federal health advisers previously split on whether the test detects disease early enough to save lives and noted a lack of data on mortality reduction.

    Why it matters

    The review concerns a novel category of multi-cancer detection tests that aim to transform early diagnosis for dozens of malignancies using a single blood draw. The advisory panel cautioned that the tool must not replace established screenings for breast, cervical, colorectal, and lung cancers. The Food and Drug Administration will now consider the committee's recommendations before making a final regulatory determination.

    What is confirmed

    • An advisory committee to the U.S. Food and Drug Administration voted that the benefits of Grail's Galleri blood test outweigh its risks.
    • The panel voted 7-2 that the benefits outweigh risks and 6-4 that the test is effective.
    • The vote does not constitute final approval from the FDA.

    Still unconfirmed

    • The FDA will follow the advisory panel's recommendation to approve the test.

    What to watch next

    • The final regulatory decision by the U.S. Food and Drug Administration regarding the Galleri test.
    Sources used for this update (3)
    1. cancerletter.com — The Galleri MCD vote: What FDA asked its advisors to ignore
    2. cancerexplained.org — FDA Advisers Back a Multi-Cancer Blood Test: What the Vote ...
    3. www.survivornet.com — What a Key FDA Vote on a New Cancer Detection Test Could Mean ...
    confidence 100%

  6. FDA Panel Narrowly Backs Grail Multi-Cancer Blood Test

    An advisory committee to the U.S. food and drug administration voted to support Grail's Galleri blood test, concluding that its benefits outweigh its risks despite concerns over its reliability and effectiveness. The screening tool aims to detect signs of more than fifty cancer types in apparently healthy people before symptoms appear. However, federal health advisers split on whether the test catches disease early enough to save lives and highlighted data gaps regarding whether it reduces mortality. The panel emphasized that the test should not replace standard screening for breast, cervical, colorectal, and lung cancers.

    Why it matters

    The premarket approval application for the Galleri test faced a major regulatory hurdle as reviewers evaluated its performance in early cancer detection. If eventually approved by regulators, the multi-cancer screening tool could significantly reshape early detection methods. The panel's narrow backing reflects ongoing scientific debate over balancing innovation with rigorous proof of clinical benefit.

    What is confirmed

    • An FDA panel voted to back Grail's Galleri multi-cancer early detection blood test.
    • The panel determined there was a reasonable assurance of safety for the test's proposed use.
    • The test is designed to screen for more than fifty types of cancer before symptoms appear.
    • Advisers stated that the blood test should not replace guideline-recommended screening for breast, cervical, colorectal, and lung cancers.
    • The panel called for more data on whether testing reduces mortality.

    Still unconfirmed

    • Federal health advisers expressed doubts about how definitive the results may be.

    What to watch next

    • Final regulatory decision by the U.S. Food and Drug Administration on the premarket approval application for the Galleri test
    • Release of additional data regarding whether the multi-cancer blood test reduces mortality
    Sources used for this update (6)
    1. www.thecardiologyadvisor.com — FDA Panel Narrowly Backs Multi-Cancer Blood Test Despite Doubts It Works
    2. rocketnews.com — Will FDA advisers recommend a multi-cancer blood test for ...
    3. www.chicagotribune.com — Grail’s cancer blood test faces high-stakes FDA review
    4. www.medscape.com — FDA Panel Votes on Multicancer Test, Highlights Data Gaps
    5. theclinicaltimes.com — FDA advisers back Grail’s Galleri cancer blood test
    6. www.empr.com — FDA Panel Narrowly Backs Multi-Cancer Blood Test Despite ...
    confidence 95%

  7. FDA Advisers Back Grail Multi-Cancer Blood Test

    U.S. food and drug administration advisers voted to back grail's multi-cancer early detection blood test, concluding that its benefits outweigh its risks. The panel voted on the premarket approval application for the galleri test, which aims to spot early signs of more than fifty types of cancer before symptoms appear. While federal health advisers expressed doubts about how definitive the results may be and whether the test works, they determined there was a reasonable assurance of safety for its proposed use.

    Why it matters

    Multi-cancer early detection blood tests represent a major frontier in oncology, seeking to identify numerous malignancies from a single draw before physical symptoms emerge. Panel members emphasized that the first-of-a-kind diagnostic tool should not replace standard medical guideline-recommended cancer screenings. The advisory vote precedes a final decision by the agency regarding market approval.

    What is confirmed

    • U.S. Food and Drug Administration advisers voted to back a multi-cancer early detection blood test from Grail.
    • The test aims to spot early signs of more than 50 types of cancer before symptoms appear.
    • Panel members advised that the blood test should not be used to replace medical guideline-recommended cancer screenings.

    Still unconfirmed

    • Panel members narrowly backed the test despite doubts over its effectiveness.

    What to watch next

    • Final FDA decision on the premarket approval application for the Galleri test.
    Sources used for this update (14)
    1. Reuters — Grail rallies as FDA staff flags no major concerns for multi-cancer test
    2. NPR — Will FDA advisers recommend a multi-cancer blood test for approval? They'll vote
    3. wsj.com — Opinion | The Galleri Result That Could Matter Most
    4. Nature — Performance and safety of a multi-cancer early detection test: the PATHFINDER 2 study
    5. University of Exeter News — First papers published in major NHS cancer blood test trial
    6. Investor's Business Daily — The Holy Grail In Cancer? FDA Mulls New Blood Tests.
    7. Mayo Clinic News Network — Multicancer blood test detects 17 cancer types in large prospective study
    8. OHSU News — PATHFINDER 2 findings advance multi-cancer early detection blood testing
    9. STAT — FDA advisory panel endorses Grail blood test for cancer, saying benefits outweigh risks
    10. www.biopharmadive.com — Grail multicancer detection test wins FDA advisers’ backing
    11. medicalxpress.com — FDA panel narrowly backs multi-cancer blood test despite doubts it works
    12. www.fox5ny.com — FDA-endorsed blood test can spot early signs of more than 50 types of cancer, drugmaker says
    confidence 100%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community